Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.
The natural targets of anti-phospholipid antibodies (aPL) and the stimuli that induce them remain unknown. Apoptotic cells have been proposed as both potential targets and immunogens for anti-phospholipid antibodies. Demonstration of selective recognition by anti-phospholipid antibodies provides support for apoptotic cells as antigenic targets. Here, we summarize data showing that prothrombin (PT) binds to apoptotic, but not viable, cells, and that apoptotic-cell bound prothrombin provides a target for human polyclonal and murine monoclonal lupus anticoagulant (LA) antibodies. We discuss findings for two monoclonal lupus anticoagulant antibodies that have high (antibody 29J3-62) or low (antibody 29I4-24) affinity, respectively, for soluble prothrombin. Despite their very different affinities for soluble prothrombin, both monoclonal antibodies reacted similarly with prothrombin bound to phospholipid or apoptotic cells. Furthermore, both antibodies enhanced the binding of prothrombin to apoptotic cells. We propose that the recognition of apoptotic cells by these prothrombin-dependent monoclonal antibodies provides a paradigm for other anti-phospholipid autoantibodies. 29I4-24 is prototypical of phospholipid-dependent anti-phospholipid antibodies, while 29J3-62 represents a prototype for phospholipid-independent anti-phospholipid antibodies. Proteins such as prothrombin and beta2-glycoprotein I (beta2GPI) bind to apoptotic cells, thereby enhancing the recognition of apoptotic cells by anti-phospholipid antibodies. Furthermore, anti-phospholipid antibodies potentiate the interaction of these proteins with apoptotic cells. While it is unclear whether apoptotic cells are the inducing stimuli in patients with anti-phospholipid antibodies or even whether anti-phospholipid antibodies interact with apoptotic cells in vivo, it is nonetheless clear that anti-phospholipid antibodies have the potential to affect both the procoagulant activity and the uptake and clearance of apoptotic cells.
Rauch
Joyce
J
Division of Rheumatology, Department of Medicine, Research Institute of the McGill University Health Centre, The Montreal General Hospital , McGill University, Montreal, Quebec H3G 1A4, Canada. joyce.rauch@mcgill.ca
D'Agnillo
Paolo
P
Subang
Rebecca
R
Levine
Jerrold S
JS
D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000502:physiology*; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000925:Anticoagulants / Q000737:chemistry; D000941:Antigens / Q000737:chemistry; D017209:Apoptosis; D001665:Binding Sites; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006023:Glycoproteins / Q000737:chemistry; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D008177:Lupus Vulgaris / Q000378:metabolism; D051379:Mice; D010743:Phospholipids / Q000737:chemistry; D011485:Protein Binding; D011516:Prothrombin / Q000737:chemistry*; D053482:beta 2-Glycoprotein I
D017152:Antibodies, Antiphospholipid; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D000941:Antigens; D006023:Glycoproteins; D007074:Immunoglobulin G; D010743:Phospholipids; D053482:beta 2-Glycoprotein I; D011516:Prothrombin